Hims & Hers Health Inc has reiterated its 2025 revenue forecast after posting better-than-expected sales for the first ...

Hims & Hers Health ( HIMS) shares surged 8% Tuesday, a day after the health and wellness platform posted better-than-expected ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

As summer approaches, millions of Americans are turning to weight-loss injections in hopes of shedding pounds—fast. Roughly ...

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...

The Ohio Board of Pharmacy recently revoked the licenses of four Ohio medical spas, with concerns over the sourcing and ...

A major international study has found that semaglutide, a drug already used to treat type 2 diabetes and obesity, can ...

Hims & Hers Health reports strong Q1 results with 111% revenue growth, 38% subscriber growth, and sets 2030 targets. Read ...

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

Mass Gen's Dr. Ali Raja explains why some were sent to the emergency room after using semaglutide injections. Raja says some of the symptoms people experienced won't require an ER visit. Raja says not ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.